An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. - Liu J; Burris H; Wang JS; Barroilhet L; Gutierrez M; Wang Y; Vaze A; Commerford R; Royer-Joo S; Choeurng V; Humke E; Moore K (Gynecologic oncology, 2021)